Molecular diagnostics in chronic lymphocytic leukemia - Pathogenetic and clinical implications

Leukemia and Lymphoma

Volumn 49, Issue 5, 2008, Pages 864-873

  Zenz, Thorsten ^a   Mertens, Daniel ^a,b   Döhner, Hartmut ^a   Stilgenbauer, Stephan ^a  

^a UNIVERSITY OF ULM   (Germany)

^b DKTZ   (Germany)

Author keywords

Cytogenetics; Drug resistance; Lymphoid leukemia; Molecular genetics

Indexed keywords

ALEMTUZUMAB; ALKYLATING AGENT; ANTINEOPLASTIC AGENT; ATM PROTEIN; CD40 LIGAND; CPG OLIGODEOXYNUCLEOTIDE; DEATH ASSOCIATED PROTEIN KINASE; DEPSIPEPTIDE; FLAVOPIRIDOL; FLUDARABINE; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IMMUNOGLOBULIN HEAVY CHAIN; INTERLEUKIN 2; LENALIDOMIDE; MESSENGER RNA; MICRORNA; MITOGEN ACTIVATED PROTEIN KINASE; OFATUMUMAB; PROTEIN KINASE ZAP 70; PROTEIN P53; PURINE DERIVATIVE; ROMIDEPSIN; STEROID; THYMIDINE KINASE;

AUTOLOGOUS STEM CELL TRANSPLANTATION; CANCER CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER REGRESSION; CANCER SURVIVAL; CHROMOSOME 11Q; CHROMOSOME 13Q; CHROMOSOME 17P; CHROMOSOME ABERRATION; CHROMOSOME BANDING PATTERN; CHROMOSOME DELETION; CHROMOSOME MUTATION; CHROMOSOME TRANSLOCATION; CLINICAL FEATURE; CLINICAL TRIAL; COMPARATIVE GENOMIC HYBRIDIZATION; CYTOGENETICS; DISEASE COURSE; DNA METHYLATION; DRUG MEGADOSE; FLUORESCENCE IN SITU HYBRIDIZATION; GENE EXPRESSION PROFILING; GENETIC ASSOCIATION; GENETIC CORRELATION; GENETIC EPIGENESIS; GENETIC RISK; HUMAN; LYMPHADENOPATHY; LYMPHATIC LEUKEMIA; MUTATIONAL ANALYSIS; OVERALL SURVIVAL; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; SEQUENCE ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SURVIVAL TIME; TREATMENT RESPONSE; TRISOMY 12;

CYTOGENETIC ANALYSIS; HUMANS; LEUKEMIA, LYMPHOCYTIC, CHRONIC, B-CELL; MOLECULAR DIAGNOSTIC TECHNIQUES; PROGNOSIS;

EID: 46749108058     PISSN: 10428194     EISSN: 10292403     Source Type: Journal    
DOI: 10.1080/10428190701882955     Document Type: Review

References (60)

1. Chiorazzi, N., Rai, K. R. and Ferrarini, M. (2005) Chronic lymphocytic leukaemia. N Engl J Med, 352, pp. 804-815.
2. Montserrat, E. (2006) New prognostic markers in CLL. Hematol Am Soc Hematol Educ Program, pp. 279-284.
3. Juliusson, G., Oscier, D. G., Fitchett, M., Ross, F. M., Stockdill, G. and Mackie, M. J. (1990) Prognostic subgroups in B-cell chronic lymphocytic leukemia defined by specific chromosomal abnormalities. N Engl J Med, 323, pp. 720-724.
4. Mayr, C., Speicher, M. R., Kofler, D. M., Buhmann, R., Strehl, J. and Busch, R. (2006) Chromosomal translocations are associated with poor prognosis in chronic lymphocytic leukemia. Blood, 107, pp. 742-751.
5. Dicker, F., Schnittger, S., Haferlach, T., Kern, W. and Schoch, C. (2006) Immunostimulatory oligonucleotide-induced metaphase cytogenetics detect chromosomal aberrations in 80% of CLL patients: A study of 132 CLL cases with correlation to FISH, IgVH status, and CD38 expression. Blood, 108, pp. 3152-3160.
6. Haferlach, C., Dicker, F., Schnittger, S., Kern, W. and Haferlach, T. (2007) Comprehensive genetic characterization of CLL: A study on 506 cases analysed with chromosome banding analysis, interphase FISH, IgV(H) status and immunophenotyping. Leukemia, 21, pp. 2442-2451.
7. Dohner, H., Stilgenbauer, S., Benner, A., Leupolt, E., Krober, A. and Bullinger, L. (2000) Genomic aberrations and survival in chronic lymphocytic leukaemia. N Engl J Med, 343, pp. 1910-1916.
8. Krober, A., Bloehdorn, J., Hafner, S., Buhler, A., Seiler, T. and Kienle, D. (2006) Additional genetic high-risk features such as 11q deletion, 17p deletion, and V3-21 usage characterize discordance of ZAP-70 and VH mutation status in chronic lymphocytic leukemia. J Clin Oncol, 24, pp. 969-975.
9. Catovsky, D., Richards, S., Matutes, E., Oscier, D., Dyer, M JS and Bezares, R. F. (2007) Assessment of fludarabine plus cyclophosphamide for patients with chronic lymphocytic leukaemia (the LRF CLL4 Trial): A randomised controlled trial. The Lancet, 370, pp. 230-239.
10. Stilgenbauer, S., Winkler, D., Buhler, A., Zenz, T., Groner, S. and Busch, R. (2007) Subcutaneous alemtuzumab (MabCampath) in fludarabine-refractory CLL (CLL2H Trial of the GCLLSG). Blood, 118, p. 918A.
11. Dohner, H., Stilgenbauer, S., James, M. R., Benner, A., Weilguni, T. and Bentz, M. (1997) 11q deletions identify a new subset of B-cell chronic lymphocytic leukaemia characterized by extensive nodal involvement and inferior prognosis. Blood, 89, pp. 2516-2522.
12. Dohner, H., Fischer, K., Bentz, M., Hansen, K., Benner, A. and Cabot, G. (1995) p53 gene deletion predicts for poor survival and non-response to therapy with purine analogs in chronic B-cell leukaemias. Blood, 85, pp. 1580-1589.
13. Keating, M. J., Flinn, I., Jain, V., Binet, J. L., Hillmen, P. and Byrd, J. (2002) Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: Results of a large international study. Blood, 99, pp. 3554-3561.
14. Grever, M. R., Lucas, D. M., Johnson, A. J. and Byrd, J. C. (2007) Novel agents and strategies for treatment of p53-defective chronic lymphocytic leukemia. Best Pract Res Clin Haematol, 20, pp. 545-556.
15. Schwaenen, C., Nessling, M., Wessendorf, S., Salvi, T., Wrobel, G. and Radlwimmer, B. (2004) Automated array-based genomic profiling in chronic lymphocytic leukemia: Development of a clinical tool and discovery of recurrent genomic alterations. Proc Natl Acad Sci USA, 101, pp. 1039-1044.
16. Pfeifer, D., Pantic, M., Skatulla, I., Rawluk, J., Kreutz, C. and Martens, U. M. (2007) Genome-wide analysis of DNA copy number changes and LOH in CLL using high-density SNP arrays. Blood, 109, pp. 1202-1210.
17. Rosenwald, A., Alizadeh, A. A., Widhopf, G., Simon, R., Davis, R. E. and Yu, X. (2001) Relation of gene expression phenotype to immunoglobulin mutation genotype in B cell chronic lymphocytic leukaemia. J Exp Med, 194, pp. 1639-1647.
18. Klein, U., Tu, Y., Stolovitzky, G. A., Mattioli, M., Cattoretti, G. and Husson, H. (2001) Gene expression profiling of B cell chronic lymphocytic leukemia reveals a homogeneous phenotype related to memory B cells. J Exp Med, 194, pp. 1625-1638.
19. Haslinger, C., Schweifer, N., Stilgenbauer, S., Dohner, H., Lichter, P. and Kraut, N. (2004) Microarray gene expression profiling of B-cell chronic lymphocytic leukemia subgroups defined by genomic aberrations and VH mutation status. J Clin Oncol, 22, pp. 3937-3949.
20. Rosenwald, A., Chuang, E. Y., Davis, R. E., Wiestner, A., Alizadeh, A. A. and Arthur, D. C. (2004) Fludarabine treatment of patients with chronic lymphocytic leukemia induces a p53-dependent gene expression response. Blood, 104, pp. 1428-1434.
21. Vallat, L. D., Park, Y., Li, C. and Gribben, J. G. (2007) Temporal genetic program following B-cell receptor cross-linking: Altered balance between proliferation and death in healthy and malignant B cells. Blood, 109, pp. 3989-3997.
22. Rodriguez, A., Villuendas, R., Yanez, L., Gomez, M. E., Diaz, R. and Pollan, M. (2007) Molecular heterogeneity in chronic lymphocytic leukemia is dependent on BCR signaling: Clinical correlation. Leukemia, 21, pp. 1984-1991.
23. Calin, G. A., Dumitru, C. D., Shimizu, M., Bichi, R., Zupo, S. and Noch, E. (2002) Frequent deletions and down-regulation of micro-RNA genes miR15 and miR16 at 13q14 in chronic lymphocytic leukemia. Proc Natl Acad Sci USA, 99, pp. 15524-15529.
24. Calin, G. A., Ferracin, M., Cimmino, A., Di Leva, G, Shimizu, M. and Wojcik, S. E. (2005) A MicroRNA signature associated with prognosis and progression in chronic lymphocytic leukemia. N Engl J Med, 27:353, pp. 1793-1801.
25. Borkhardt, A., Fuchs, U. and Tuschl, T. (2006) MicroRNA in chronic lymphocytic leukemia. N Engl J Med, 354, pp. 524-525.
26. Fulci, V., Chiaretti, S., Goldoni, M., Azzalin, G., Carucci, N. and Tavolaro, S. (2007) Quantitative technologies establish a novel microRNA profile of chronic lymphocytic leukemia. Blood, 109, pp. 4944-4951.
27. He, L., He, X., Lowe, S. W. and Hannon, G. J. (2007) microRNAs join the p53 network - another piece in the tumour-suppression puzzle. Nat Rev Cancer, 7, pp. 819-822.
28. He, L., He, X., Lim, L. P., de Stanchina, E., Xuan, Z. and Liang, Y. (2007) A microRNA component of the p53 tumour suppressor network. Nature, 447, pp. 1130-1134.
29. Esteller, M. (2007) Cancer epigenomics: DNA methylomes and histone-modification maps. Nat Rev Genet, 8, pp. 286-298.
30. Smith, L. T., Otterson, G. A. and Plass, C. (2007) Unraveling the epigenetic code of cancer for therapy. Trends Genetics, 23, pp. 449-456.
31. Jenuwein, T. and Allis, C. D. (2001) Translating the histone code. Science, 293, pp. 1074-1080.
32. Rippe, K. (2007) Dynamic organization of the cell nucleus. Curr Opin Genet Dev, 17, pp. 373-380.
33. Wahlfors, J., Hiltunen, H., Heinonen, K., Hamalainen, E., Alhonen, L. and Janne, J. (1992) Genomic hypomethylation in human chronic lymphocytic leukemia. Blood, 80, pp. 2074-2080.
34. Raval, A., Byrd, J. C. and Plass, C. (2006) Epigenetics in chronic lymphocytic leukemia. Semin Oncol, 33, pp. 157-166.
35. Plass, C., Byrd, J. C., Raval, A., Tanner, S. M. and de la Chapelle, A. (2007) Molecular profiling of chronic lymphocytic leukaemia: Genetics meets epigenetics to identify predisposing genes. Br J Haematol, 139, pp. 744-752.
36. Smiraglia, D. J. and Plass, C. (2002) The study of aberrant methylation in cancer via restriction landmark genomic scanning. Oncogene, 21, pp. 5414-5426.
37. Rush, L. J., Raval, A., Funchain, P., Johnson, A. J., Smith, L. and Lucas, D. M. (2004) Epigenetic profiling in chronic lymphocytic leukemia reveals novel methylation targets. Cancer Res, 64, pp. 2424-2433.
38. Hanada, M., Delia, D., Aiello, A., Stadtmauer, E. and Reed, J. C. (1993) bcl-2 gene hypomethylation and high-level expression in B-cell chronic lymphocytic leukemia. Blood, 82, pp. 1820-1828.
39. Yuille, M. R., Condie, A., Stone, E. M., Wilsher, J., Bradshaw, P. S. and Brooks, L. (2001) TCL1 is activated by chromosomal rearrangement or by hypomethylation. Genes Chromosomes Cancer, 30, pp. 336-341.
40. Raval, A., Lucas, D. M., Matkovic, J. J., Bennett, K. L., Liyanarachchi, S. and Young, D. C. (2005) TWIST2 demonstrates differential methylation in immunoglobulin variable heavy chain mutated and unmutated chronic lymphocytic leukemia. J Clin Oncol, 23, pp. 3877-3885.
41. Raval, A., Tanner, S. M., Byrd, J. C., Angerman, E. B., Perko, J. D. and Chen, S. S. (2007) Downregulation of death-associated protein kinase 1 (DAPK1) in chronic lymphocytic leukemia. Cell, 129, pp. 879-890.
42. Mertens, D., Wolf, S., Schroeter, P., Schaffner, C., Dohner, H. and Stilgenbauer, S. (2002) Down-regulation of candidate tumor suppressor genes within chromosome band 13q14.3 is independent of the DNA methylation pattern in B-cell chronic lymphocytic leukemia. Blood, 99, pp. 4116-4121.
43. Mertens, D., Wolf, S., Tschuch, C., Mund, C., Kienle, D. and Ohl, S. (2006) Allelic silencing at the tumor-suppressor locus 13q14.3 suggests an epigenetic tumor-suppressor mechanism. Proc Natl Acad Sci USA, 103, pp. 7741-7746.
44. Crespo, M., Bosch, F., Villamor, N., Bellosillo, B., Colomer, D. and Rozman, M. (2003) ZAP-70 expression as a surrogate for immunoglobulin-variable-region mutations in chronic lymphocytic leukemia. N Engl J Med, 348, pp. 1764-1775.
45. Orchard, J. A., Ibbotson, R. E., Davis, Z., Wiestner, A., Rosenwald, A. and Thomas, P. W. (2004) ZAP-70 expression and prognosis in chronic lymphocytic leukaemia. Lancet, 363, pp. 105-111.
46. Rassenti, L. Z., Huynh, L., Toy, T. L., Chen, L., Keating, M. J. and Gribben, J. G. (2004) ZAP-70 compared with immunoglobulin heavy-chain gene mutation status as a predictor of disease progression in chronic lymphocytic leukemia. N Engl J Med, 351, pp. 893-901.
47. Corcoran, M., Parker, A., Orchard, J., Davis, Z., Wirtz, M. and Schmitz, O. J. (2005) ZAP-70 methylation status is associated with ZAP-70 expression status in chronic lymphocytic leukemia. Haematologica, 90, pp. 1078-1088.
48. Byrd, J. C., Shinn, C., Ravi, R., Willis, C. R., Waselenko, J. K. and Flinn, I. W. (1999) Depsipeptide (FR901228): A novel therapeutic agent with selective, in vitro activity against human B-cell chronic lymphocytic leukemia cells. Blood, 94, pp. 1401-1408.
49. Gaidano, G., Ballerini, P., Gong, J. Z., Inghirami, G., Neri, A. and Newcomb, E. W. (1991) p53 mutations in human lymphoid malignancies: association with Burkitt lymphoma and chronic lymphocytic leukaemia. Proc Natl Acad Sci USA, 88, pp. 5413-5417.
50. Trbusek, M., Malcikova, J., Smardova, J., Kuhrova, V., Mentzlova, D. and Francova, H. (2006) Inactivation of p53 and deletion of ATM in B-CLL patients in relation to IgVH mutation status and previous treatment. Leukaemia, 20, pp. 1159-1161.
51. Schaffner, C., Stilgenbauer, S., Rappold, G. A., Dohner, H. and Lichter, P. (1999) Somatic ATM mutations indicate a pathogenic role of ATM in B-cell chronic lymphocytic leukaemia. Blood, 94, pp. 748-753.
52. Austen, B., Powell, J. E., Alvi, A., Edwards, I., Hooper, L. and Starczynski, J. (2005) Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL. Blood, 106, pp. 3175-3182.
53. Austen, B., Skowronska, A., Baker, C., Powell, J. E., Gardiner, A. and Oscier, D. (2007) Mutation status of the residual ATM allele is an important determinant of the cellular response to chemotherapy and survival in patients with chronic lymphocytic leukemia containing an 11q deletion. J Clin Oncol, 25, pp. 5448-5457.
54. Grever, M. R., Lucas, D. M., Dewald, G. W., Neuberg, D. S., Reed, J. C. and Kitada, S. (2007) Comprehensive assessment of genetic and molecular features predicting outcome in patients with chronic lymphocytic leukemia: Results from the US Intergroup Phase III Trial E2997. J Clin Oncol, 25, pp. 799-804.
55. Pettitt, A. R., Sherrington, P. D., Stewart, G., Cawley, J. C., Taylor, A. M. and Stankovic, T. (2001) p53 dysfunction in B-cell chronic lymphocytic leukemia: Inactivation of ATM as an alternative to TP53 mutation. Blood, 98, pp. 814-822.
56. Damle, R. N., Wasil, T., Fais, F., Ghiotto, F., Valetto, A. and Allen, S. L. (1999) Ig V gene mutation status and CD38 expression as novel prognostic indicators in chronic lymphocytic leukaemia. Blood, 94, pp. 1840-1847.
57. Hamblin, T. J., Davis, Z., Gardiner, A., Oscier, D. G. and Stevenson, F. K. (1999) Unmutated Ig V(H) genes are associated with a more aggressive form of chronic lymphocytic leukaemia. Blood, 94, pp. 1848-1854.
58. Le Garff-Tavernier, M, Ticchioni, M., Brissard, M., Salmon, C., Raynaud, S. and Davi, F. (2007) National standardization of ZAP-70 determination by flow cytometry: The French experience. Clin Cytom B, 2, pp. 103-108.
59. Heintel, D., Kienle, D., Shehata, M., Krober, A., Kroemer, E. and Schwarzinger, I. (2005) High expression of lipoprotein lipase in poor risk B-cell chronic lymphocytic leukemia. Leukemia, 19, pp. 1216-1223.
60. van't Veer, M B, Brooijmans, A. M., Langerak, A. W., Verhaaf, B., Goudswaard, C. S. and Graveland, W. J. (2006) The predictive value of lipoprotein lipase for survival in chronic lymphocytic leukemia. Haematologica, 91, pp. 56-63.